An international research consortium, spearheaded by the renowned Levenberg Laboratory at the Technion-Israel Institute of Technology, has unveiled a groundbreaking,…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial for Type 2 Diabetes, Signaling Major Therapeutic Advance
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Novo Nordisk’s new weight loss treatment inferior to Lilly’s tirzepatide
Novo Nordisk, a global leader in diabetes and obesity care, announced on Monday that its investigational weight loss treatment, CagriSema,…
Read More
Novo Nordisk’s triple agonist delivers up to 19.7% average weight loss in Phase 2 trial
Novo Nordisk, a global leader in diabetes and obesity care, announced a significant advancement in its weight management pipeline with…
Read MoreYOU MAY HAVE MISSED
